Nervgen Pharma Corp Stock Price Prediction
| NGEN Stock | CAD 3.00 0.13 4.15% |
Oversold Vs Overbought
47
Oversold | Overbought |
EPS Estimate Next Quarter (0.08) | EPS Estimate Current Year (0.33) | EPS Estimate Next Year (0.45) | Wall Street Target Price 4.5 | EPS Estimate Current Quarter (0.09) |
Using NervGen Pharma hype-based prediction, you can estimate the value of NervGen Pharma Corp from the perspective of NervGen Pharma response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in NervGen Pharma to buy its stock at a price that has no basis in reality. In that case, they are not buying NervGen because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
NervGen Pharma after-hype prediction price | CAD 2.96 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
NervGen |
NervGen Pharma After-Hype Price Prediction Density Analysis
As far as predicting the price of NervGen Pharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in NervGen Pharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of NervGen Pharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
NervGen Pharma Estimiated After-Hype Price Volatility
In the context of predicting NervGen Pharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on NervGen Pharma's historical news coverage. NervGen Pharma's after-hype downside and upside margins for the prediction period are 0.15 and 8.86, respectively. We have considered NervGen Pharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
NervGen Pharma is dangerous at this time. Analysis and calculation of next after-hype price of NervGen Pharma Corp is based on 3 months time horizon.
NervGen Pharma Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as NervGen Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading NervGen Pharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with NervGen Pharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.42 | 5.90 | 0.04 | 0.01 | 2 Events / Month | 1 Events / Month | In a few days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
3.00 | 2.96 | 1.33 |
|
NervGen Pharma Hype Timeline
NervGen Pharma Corp is now traded for 3.00on TSX Venture Exchange of Canada. The entity has historical hype elasticity of -0.04, and average elasticity to hype of competition of 0.01. NervGen is forecasted to decline in value after the next headline, with the price expected to drop to 2.96. The average volatility of media hype impact on the company price is over 100%. The price drop on the next news is expected to be -1.33%, whereas the daily expected return is now at 0.42%. The volatility of related hype on NervGen Pharma is about 47200.0%, with the expected price after the next announcement by competition of 3.01. About 23.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.38. NervGen Pharma Corp had not issued any dividends in recent years. Assuming the 90 days trading horizon the next forecasted press release will be in a few days. Check out NervGen Pharma Basic Forecasting Models to cross-verify your projections.NervGen Pharma Related Hype Analysis
Having access to credible news sources related to NervGen Pharma's direct competition is more important than ever and may enhance your ability to predict NervGen Pharma's future price movements. Getting to know how NervGen Pharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how NervGen Pharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| APS | Aptose Biosciences | (0.02) | 3 per month | 6.06 | 0 | 8.00 | (10.53) | 34.00 | |
| XHB | iShares Canadian HYBrid | (0.06) | 3 per month | 0.11 | (0) | 0.51 | (0.35) | 1.52 | |
| ALA-PA | Altagas Cum Red | 0.00 | 0 per month | 0.57 | 0.09 | 1.15 | (1.06) | 3.73 | |
| ERE-UN | European Residential Real | 0.04 | 4 per month | 1.04 | 0.1 | 2.30 | (1.58) | 20.23 | |
| CLU | iShares Fundamental Hedged | 0.24 | 2 per month | 0.56 | (0.02) | 1.02 | (0.97) | 5.88 | |
| RUDB | RBC Discount Bond | 0.05 | 1 per month | 0.24 | 0.09 | 0.70 | (0.47) | 1.96 | |
| BN-PFI | Brookfield | 0.00 | 0 per month | 0.53 | 0.04 | 1.10 | (1.09) | 2.73 | |
| XEG | iShares SPTSX Capped | (0.15) | 1 per month | 0.00 | (0.06) | 2.20 | (2.24) | 8.20 |
NervGen Pharma Additional Predictive Modules
Most predictive techniques to examine NervGen price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for NervGen using various technical indicators. When you analyze NervGen charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About NervGen Pharma Predictive Indicators
The successful prediction of NervGen Pharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as NervGen Pharma Corp, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of NervGen Pharma based on analysis of NervGen Pharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to NervGen Pharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to NervGen Pharma's related companies. | 2021 | 2022 | 2023 | 2024 (projected) | Net Debt To EBITDA | 1.33 | 1.1 | 0.65 | 1.07 | Intangibles To Total Assets | 0.0264 | 0.0181 | 0.0393 | 0.0746 |
Story Coverage note for NervGen Pharma
The number of cover stories for NervGen Pharma depends on current market conditions and NervGen Pharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that NervGen Pharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about NervGen Pharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
NervGen Pharma Short Properties
NervGen Pharma's future price predictability will typically decrease when NervGen Pharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of NervGen Pharma Corp often depends not only on the future outlook of the potential NervGen Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. NervGen Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 59.6 M |
Additional Tools for NervGen Stock Analysis
When running NervGen Pharma's price analysis, check to measure NervGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NervGen Pharma is operating at the current time. Most of NervGen Pharma's value examination focuses on studying past and present price action to predict the probability of NervGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NervGen Pharma's price. Additionally, you may evaluate how the addition of NervGen Pharma to your portfolios can decrease your overall portfolio volatility.